Medical and surgical technological advances show promise for future glaucoma management.
Clinical pilot study evaluates effect after 1 month of wear.
Understand the condition’s structural, innervational, neurological, and genetic abnormalities
The expenditure of embracing new technologies is worthwhile.
Medical and surgical technological advances show promise for future glaucoma management.
Advances in drug creation would reduce cost burden of treatment for patients.
Alexis G. Malkin, OD, FAAO, and Anita Gulmiri, OD, FAAO, share highlights from their presentation, "Intersection of low vision and contact lens: unique examples of co-management," which they presented during AAOpt 2022.
ODs have the rare opportunity to engage as well as educate patients on hypertension.
Evolution of vision correction procedures, diagnostics paves way for collaborative care.
These options increase the depth of field to address the symptoms of presbyopia
Daniel G. Fuller, OD, FAAO Dipl., FSLS, shares what he wish he knew before entering the field.
Earlier and proactive use is suggested for a variety of corneal diseases
Roundtable of experts discuss impact, management of retinal disease.
Mitch Ibach, OD, FAOO, tells us about the current corneal cross-linking treatments, as well as those on the horizon.
Eyecare practitioners' top misconceptions just may surprise you.
Jacqueline Theis, OD, FAAO, gives key takeaways from her AAOpt 2022 meeting presentation, "Ocular and visual complications of Parkinson's disease."
Expert advice offers key practice management tips for making presbyopia drops an integrated part of a clinical armamentarium.
Enthusiasm regarding the acceleration of technology advances, including retinal monitoring centers, that can be used to help prevent disease progression for patients with eye diseases.
Proper screenings, treatment, management needed for this increasingly prevalent disease.
Consider 4 conditions when treating this patient population.
Protecting children’s eye health will demand a focus on vision and learning through better nutrition, myopia management, and disease prevention.
Jeff Nau, PhD, president and CEO of Oyster Point Pharma shares an update on the company's Tyrvaya product.